ABIONYX Pharma, a company focused on developing innovative therapies using recombinant human apoA-I, announced that its Phase 2b RACERS study on sepsis has been selected for a poster presentation at the 2024 American Society of Nephrology (ASN) Annual Meeting. The presentation will highlight new clinical findings demonstrating the positive impact of CER-001 on cognitive impairment, specifically “brain fog.”
The data reveal that CER-001 mitigates brain dysfunction by downregulating the enzyme indolamine-2,3-dioxygenase 1 (IDO1), a key mediator of the kynurenine pathway in sepsis. IDO1, known to be upregulated during inflammation and associated with cognitive dysfunction, was observed to be downregulated post-treatment with CER-001. This downregulation subsequently reduces the production of potentially neurotoxic metabolites.
Clinical results from the RACERS study demonstrated a significant increase in tryptophan levels during treatment and an observed increase in neuroprotective kynurenic acid (KYNA). These findings support the hypothesis that CER-001 differentially regulates tryptophan metabolism, leading to neuroprotection.
The study’s lead investigator emphasized the significance of these findings, stating that CER-001’s ability to attenuate systemic inflammation, regulate IDO1, and reduce neuroactive metabolites and waste accumulation holds promise for improving cognitive function in sepsis patients. These results further solidify the strong data from the RACERS study and support the efficacy of CER-001.
This new data validates the potential of CER-001 in treating brain fog associated with sepsis and encourages exploring its use in other neuroinflammatory conditions. The poster presentation will provide a detailed analysis of the brain-kidney interaction during sepsis-associated acute kidney injury based on the findings of the RACERS study.
Source link: http://www.businesswire.com/news/home/20241024057906/fr/
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
